Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Q4 Earnings Call Highlights
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant's treatment for eye disease fails late-stage trial
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) & Immunovant (NASDAQ:IMVT)
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Immunovant Announces Pricing of $550 Million Common Stock Financing
55,524 Shares in Immunovant, Inc. $IMVT Purchased by Capital Fund Management S.A.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript
Why Immunovant Stock Blasted Higher Today
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?